BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: editorialoffice@wjgnet.com http://www.wjgnet.com

ESPS Peer-review Report
Name of Journal: World Journal of Clinical Oncology
ESPS Manuscript NO: 8234
Title: Evolution of breast cancer therapeutics: Brk's role in breast cancer and hope for Brk targeted therapy
Reviewer code: 02616017
Science editor: Huan-Huan Zhai
Date sent for review: 2013-12-22 20:53
Date reviewed: 2014-01-03 10:19

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

Brk is over expressed in many types of cancers. Over-expression of Brk activates crucial signaling pathways MAPK, AKT and FAK, and promotes proliferation, invasion and metastasis. Correspondingly, inhibition of Brk tyrosine kinase activity or knock down Brk expression diminished proliferation and tumor growth. Moreover, Brk integrates with other key pathways, such as EGFR, HER2 and IGFR, which might contribute to the therapeutic resistance of current target drugs. It is clearly that Brk is a key gene driving breast tumor development. Therefore, Brk can be explored as a therapeutic target. The manuscript comprehensively summarized the biological function of Brk, specially focusing on how to develop novel therapy based on biochemical properties and biological functions. Several suggestions for publication: The review should focus on most recent research progress of Brk, description of current tyrosine kinase inhibitors can be more simplified ; the abstract and introduction overlaps too much, some sentences need modified; the manuscript could be reduced 25% and reference could be limited to less than 80.